{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:17:00Z","timestamp":1764260220257},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,8,1]]},"DOI":"10.2169\/internalmedicine.8733-21","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T22:10:00Z","timestamp":1647036600000},"page":"2301-2305","source":"Crossref","is-referenced-by-count":8,"title":["Two Cases of Intraabdominal Bleeding Caused by Hepatocellular Carcinoma Rupture Soon after the Initiation of Chemotherapy with Lenvatinib"],"prefix":"10.2169","volume":"61","author":[{"given":"Aya","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Gastroenterology & Hepatology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology & Hepatology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Uchiya","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology & Hepatology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihito","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology & Hepatology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Nakazawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology & Hepatology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayoko","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology & Hepatology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology & Hepatology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Mochida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology & Hepatology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Tohyama O, Matsui J, Kodama KS, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014: 638747, 2014.","DOI":"10.1155\/2014\/638747"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. Lancet 391: 1163-1173, 2018.","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30: 52-60, 2010.","DOI":"10.1055\/s-0030-1247132"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hiraoka A, Kumada T, Kariyama K, et al. Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: multicenter analysis. Hepatol Res 49: 111-117, 2019.","DOI":"10.1111\/hepr.13243"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Fuchigami A, Imai Y, Uchida Y, et al. Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome. PLOS ONE 15: e0231427, 2020.","DOI":"10.1371\/journal.pone.0231427"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Sho T, Suda G, Ogawa K, et al. Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting. JGH Open 4: 54-60, 2020.","DOI":"10.1002\/jgh3.12209"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Takahashi A, Moriguchi M, Seko Y, et al. Early tumor shrinkage as a predictive factor for outcomes in hepatocellular carcinoma patients treated with lenvatinib: a multicenter analysis. Cancers 12: 754, 2020.","DOI":"10.3390\/cancers12030754"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kuzuya T, Ishigami M, Ito T, et al. Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma. Hepatol Res 50: 374-381, 2020.","DOI":"10.1111\/hepr.13452"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yoshida H, Mamada Y, Taniai N, et al. Spontaneous ruptured hepatocellular carcinoma. Hepatol Res 46: 13-21, 2016.","DOI":"10.1111\/hepr.12498"},{"key":"10","unstructured":"10. Kudo M, Izumi N, Kokudo M, et al. Report of the 22nd nationwide follow-up survey of primary liver cancer in Japan (2012-2013). Hepatol Res. Forthcoming."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sahu SK, Chawla YK, Dhiman RK, et al. Rupture of hepatocellular carcinoma: a review of literature. J Clin Exp Hepatol 9: 245-256, 2019.","DOI":"10.1016\/j.jceh.2018.04.002"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Aoki T, Kokudo N, Matsuyama Y, et al.; Liver Cancer Study Group of Japan. Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey. Ann Surg 259: 532-542, 2014.","DOI":"10.1097\/SLA.0b013e31828846de"},{"key":"13","unstructured":"13. Li J, Huang L, Liu CF, et al. Risk factors and surgical outcomes for spontaneous rupture of BCLC stages A and B hepatocellular carcinoma: a case-control study. World J Gastroenterol 27: 9121-9127, 2014."},{"key":"14","first-page":"616","volume":"57","author":"JH Sun","year":"2010","unstructured":"14. Sun JH, Wang LG, Bao HW, et al. Emergency embolization in the treatment of ruptured hepatocellular carcinoma following transcatheter arterial chemoembolization. Hepatogastroenterology 57: 616-619, 2010.","journal-title":"Hepatogastroenterology","ISSN":"http:\/\/id.crossref.org\/issn\/0172-6390","issn-type":"print"},{"key":"15","unstructured":"15. Battula N, Srinivasan P, Madanur M, et al. Ruptured hepatocellular carcinoma following chemoembolization: a western experience. Hepatobiliary Pancreat Dis Int 6: 49-51, 2007."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Rombol\u00e0 F, Caravetta A, Mollo F, Spinoso A, Peluso L, Guarino R. Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case. Acta Medica (Hradec Kralove) 54: 177-179, 2011.","DOI":"10.14712\/18059694.2016.46"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 52: 512-519, 2017.","DOI":"10.1007\/s00535-016-1263-4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ishihara K. A case of multiple intratumoral hemorrhage and rupture of hepatocellular carcinoma after starting lenvatinib. Case Rep Hepatol 2020: 6659388, 2020.","DOI":"10.1155\/2020\/6659388"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/15\/61_8733-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T03:15:15Z","timestamp":1659755715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/15\/61_8733-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":18,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8733-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]},"article-number":"8733-21"}}